Table 4. Phenotypic drug susceptibility profile and genetic sequence analysis of all cavities of each patient.
Patient Nos. | Cavity Nos. (Lobe)a | Phenotypic Drug Susceptibility profileb | Genetic sequence analysis: mutation observed (codon number)c | ||||
Sensitive | Resistant | rpoB gene | katG gene | gyrA gene | rrs gene | ||
1 | 1 (LUL), 2 (LUL), 3 (LUL) | PAS, Cfz | S, H, R, E, Km, Eto, Ofx, Mfx, Am, Cm, Z | C to T (531) | G to C (315) | A to G (94) | A to G (1401) |
2 | 1 (LUL) | Cfz, Z | S, H, R, E, K, Eto, PAS, Ofx, Mfx, Am, Cm | C to T (531) | G to C (315) | A to G (94) | A to G (1401) |
2 (LUL) | E, Km, Am, Cm, Z, Cfz | S, H, R, Eto, PAS, Ofx, Mfx | C to T (531) | G to C (315) | A to G (94) | wtd | |
3 (LLL) | E, PAS, Cfz | S, H, R, K, Eto, Ofx, Mfx, Am, Cm, Z | C to T (531) | G to C (315) | A to G (94) | A to G (1401) | |
3 | 1 (LUL), 2 (LLL), 3 (LLL) | S, Km, Am, Cfz, Cm | H, R, E, Eto, PAS, Ofx, Mfx, Z | C to T (531) | G to C (315) | A to G (94) | Wt |
4 | 1 (LUL), 2 (LUL), 3 (LUL) | Cfz | S, H, R, E, Km, Eto, PAS, Ofx, Mfx, Am, Cm, Z | C to T (531) | G to C (315) | A to G (94) | A to G (1401) |
5 | 1 (RUL) | Km, PAS, Am, Cfz, Cm | S, H, R, E, Eto, Ofx, Mfx, Z | C to T (531) | G to C (315) | A to G (94) | wt |
2 (RUL) | Km, Am, Cfz, Cm | S, H, R, E, Eto, PAS, Ofx, Mfx, Am, Z | C to T (531) | G to C (315) | A to G (94) | wt | |
3 (RLL) | Km, Am, Cfz, Cm | S, H, R, E, Eto, PAS, Ofx, Mfx, Am, Z | C to T (531) | G to C (315) | A to G (94) | wt |
LUL, Left upper lobe; LLL, left lower lobe, RUL, right upper lobe; RLL, right lower lobe.
S: Streptomycin, H:Isoniazid, R:Rifampicin, E:Ethambutol, Km:Kanamycin, Eto:Ethionamide, PAS:para-aminosalicylic acid, Ofx:Ofloxocin, Mfx:Moxifloxacin, Am:Amikacin, Cfz:Clofaziamine, Cm:Capreomycin, Z:Pyrazinamide.
Cavity isolates showing variable drug susceptibility profiles were analyzed by in-house RLBH (except for Ethambutol, PAS, Pyrazinamide, wherein phenotypic DST were repeated to confirm the variable drug susceptibility profile).
wt – wild type.